MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14712598.2026.2694689

Медицинская библиотека · Expert opinion on biological therapy · 2026

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Diomeda Federico, Natoli Valentina, Civino Adele, Ravelli Angelo

СтатьяОбзорПеревод в очереди

Аннотация

INTRODUCTION

Childhood-onset systemic lupus erythematosus (cSLE) accounts for 15-20% of all forms of SLE. It is associated with greater disease severity and requires more aggressive treatment than adult-onset SLE. Despite therapeutic advances, many patients do not achieve sustained remission, highlighting the need for more effective treatment strategies.

AREAS COVERED: This review summarizes the literature published in the past two decades on the use of biologic medications for the treatment of cSLE. It is based on the narrative analysis of recent clinical trials, observational studies and patient series or individual clinical cases. We discuss the rationale, indications, effectiveness and safety of the biologic agents utilized thus far in patients with cSLE, with a primary focus on rituximab and belimumab. In addition, we address the future perspectives of the management of cSLE.

EXPERT OPINION: The improved understanding of the mechanisms involved in immunopathogenesis of SLE has led to the development of increasing numbers of biologic agents that target specific cells or pathways. This advance has increased the therapeutic options available for the management of cSLE and holds great promise for transforming the landscape of cSLE care through the implementation of precision medicine and personalized therapeutic approaches, with the ultimate goal of reaching sustained, glucocorticoid-free disease remission.

Для цитирования: Diomeda Federico, Natoli Valentina, Civino Adele, Ravelli Angelo. Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.. Expert opinion on biological therapy. 2026. DOI: 10.1080/14712598.2026.2694689.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.